Akebia Therapeutics (AKBA) Other Non-Current Assets (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Other Non-Current Assets data on file, last reported at $56.6 million in Q1 2026.

• On a quarterly basis, Other Non-Current Assets rose 47.55% year-over-year to $56.6 million in Q1 2026; TTM through Mar 2026 was $56.6 million, a 47.55% increase from a year earlier, with the FY2025 full-year figure at $59.7 million, up 59.67% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $56.6 million, down from $59.7 million in the prior quarter.
• Over the last five years, Other Non-Current Assets for AKBA reached as high as $59.7 million in Q4 2025 and fell as low as $3.3 million in Q2 2023.
• Historically, Other Non-Current Assets has averaged $27.3 million across 5 years, with a median of $27.1 million in 2024.
• Across the five-year window, Other Non-Current Assets sank 90.42% in 2023 and soared 602.59% in 2024, its largest moves.
• Year by year, Other Non-Current Assets stood at $5.4 million in 2022, then surged by 131.25% to $12.4 million in 2023, then surged by 200.87% to $37.4 million in 2024, then soared by 59.67% to $59.7 million in 2025, then fell by 5.21% to $56.6 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Assets figures were $56.6 million in Q1 2026, $59.7 million in Q4 2025, and $40.5 million in Q3 2025.